An HPE (histopathology) or biopsy report tells you what tissue was sampled, what the pathologist saw under the microscope and the final diagnosis. In urology, the key fields differ by organ: a prostate biopsy focuses on Gleason/ISUP Grade Group and tumour involvement; a bladder TURBT report must clarify depth of invasion and whether muscle is present; a kidney or testicular cancer specimen has its own subtype, grade, margin and stage details. The report is therefore not just “positive or negative”—the exact wording can change treatment.

What sections are usually in the report?

Specimen / clinical details

This identifies where the tissue came from and how it was obtained—for example prostate core biopsy, TURBT bladder chips, renal mass nephrectomy or urethral biopsy. Correct specimen orientation and site labels can be essential.

Gross description

The pathologist describes the tissue visible to the naked eye: size, number of cores/fragments, tumour dimensions or margin orientation. This section is mainly technical but may contain useful measurements.

Microscopic description

This records what cells and tissue architecture look like. Some laboratories provide extensive microscopy; others summarise it in the final diagnosis.

Final diagnosis

This is the key interpretation: benign tissue, inflammation, dysplasia/premalignant change, or a named cancer type with relevant grade and other features.

Grade is not the same as stage

Grade describes how abnormal/aggressive the tumour looks microscopically—for example ISUP Grade Group in prostate cancer or WHO grade in some urothelial tumours. Stage describes how far the cancer has grown or spread. A high-grade small tumour and a low-grade advanced tumour are different clinical situations.

Margins

A surgical margin is the cut edge of tissue removed during surgery. “Negative/clear margin” means tumour is not seen at the inked edge; “positive margin” means tumour reaches it. Margin importance varies by cancer type and procedure and does not automatically mean additional treatment is required.

Invasion terms

• Lymphovascular invasion: tumour cells are seen within lymphatic or blood vessels.
• Perineural invasion: tumour is seen tracking around/along a nerve; significance is organ-specific.
• Muscularis propria invasion in bladder cancer: a crucial distinction because muscle-invasive disease follows a different treatment pathway.
• Extraprostatic, renal sinus, perinephric or other organ-specific extension: may contribute to pathological stage.

Immunohistochemistry (IHC)

IHC uses antibodies to detect proteins in tumour cells and can confirm tissue of origin, subtype a tumour or test predictive/prognostic markers. A list of “positive” and “negative” stains is not meaningful by itself; the pattern is interpreted by the pathologist in context.

Why biopsy and surgery reports can differ

A needle or endoscopic biopsy samples only part of a tumour. The final surgical specimen may show a different grade, greater depth of invasion or additional features that were not sampled earlier. This is called upgrading or upstaging and is a recognised limitation of sampling rather than necessarily an error.

When a second pathology review is useful

Expert review can be considered for rare tumours, unusual variants, discordant imaging/pathology, major treatment decisions based on a borderline diagnosis or when tissue quality is limited. The original slides/blocks—not only the printed report—may be needed.

An example of how to read a cancer pathology line

A phrase such as “high-grade urothelial carcinoma invading muscularis propria; lymphovascular invasion not identified” contains several separate facts: cancer type, grade, depth of invasion and one additional risk feature. The clinically decisive part may be muscle invasion, not whether lymphovascular invasion is absent. Likewise, a prostate biopsy line may combine Grade Group, percentage of core involved and perineural invasion.

Do not interpret isolated adjectives such as “poorly differentiated,” “focal” or “suspicious” without the final diagnosis and organ-specific protocol. If a report contains an addendum, molecular test or revised diagnosis, the latest integrated report should be used for treatment planning.

Urology-specific lines that can completely change the meaning of an HPE report

Prostate biopsy: look for Gleason score/ISUP Grade Group, number and length or percentage of involved cores, and adverse patterns such as cribriform or intraductal carcinoma when reported. These features are used with PSA and imaging to stratify risk.

Bladder tumour (TURBT): grade, lamina propria invasion, carcinoma in situ, lymphovascular invasion and—critically—whether muscularis propria is present and involved. ‘Muscle not seen’ is not the same as ‘muscle present and free of tumour’.

Kidney cancer: histological subtype, WHO/ISUP grade where applicable, tumour size, necrosis or sarcomatoid/rhabdoid change, margins and pathological stage. Testicular cancer reports use tumour type, lymphovascular invasion, local structures involved and margin information. The important fields therefore depend on which urological organ was sampled.

Four examples of why one pathology word can change treatment

‘High-grade’ bladder cancer confined to the mucosa is not equivalent to muscle-invasive bladder cancer; depth of invasion changes the treatment pathway. In prostate cancer, Grade Group 1 and Grade Group 5 can share the same organ but carry very different biological risk. In kidney cancer, a clear-cell RCC with sarcomatoid differentiation is not interpreted like a small low-grade papillary tumour. In testicular cancer, lymphovascular invasion can influence relapse-risk discussions even after the primary tumour is removed.

Also check whether the specimen was adequate for the question asked. A superficial bladder specimen without muscularis propria may limit staging. A prostate biopsy samples only selected cores and can under-grade a larger tumour later found at prostatectomy. A ‘negative margin’ on a surgical specimen answers a different question from a ‘negative biopsy’.

When treatment is major or the pathology is unusual, expert genitourinary pathology review can be worthwhile because tumour subtype and grade sometimes change after specialist review.

What to bring for consultation

• Complete pathology report with specimen labels.
• Original biopsy/surgery date and procedure note.
• CT/MRI/PET staging images and reports.
• Relevant tumour markers such as PSA where applicable.
• Previous pathology reports for comparison and details of prior treatment.

FAQs

Related reading

• Cancer Staging Report Explained
• Prostate MRI Report Explained
• PI-RADS Score on MRI Explained
• PSA Report Explained
• Urologist in Latur

References

• National Cancer Institute. Surgical Pathology Reports https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/pathology-reports-fact-sheet
• National Cancer Institute. Cancer Staging https://www.cancer.gov/about-cancer/diagnosis-staging/staging
• College of American Pathologists. Current Cancer Protocols https://www.cap.org/protocols-and-guidelines/cancer-protocols/current-cancer-protocols/